Spots Global Cancer Trial Database for angiogenesis inhibitor
Every month we try and update this database with for angiogenesis inhibitor cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| A Phase 1/2, Open-Label, Dose-Escalation Study of JI-101, in Patients With Advanced Solid Tumors | NCT00842335 | Advanced Solid ... | JI-101 | 18 Years - | Jubilant Innovation Ltd. | |
| Phase1b to Evaluate Safety of AMG706 in Combination With Paclitaxel or Docetaxel for Breast Cancer | NCT00322400 | Locally Recurre... | Docetaxel Paclitaxel AMG 706 | 18 Years - | Amgen | |
| Study of TRC105 and Bevacizumab in Patients With Refractory Gestational Trophoblastic Neoplasia (GTN) | NCT02664961 | Gestational Tro... Choriocarcinoma Placental Site ... Epithelioid Tro... | TRC105 Bevacizumab | 16 Years - 99 Years | Tracon Pharmaceuticals Inc. | |
| Sunitinib Malate, Hormone Ablation and Radiation Therapy in Patients With Prostate Cancer | NCT00631527 | Prostate Cancer | Leuprolide Goserelin Sunitinib Malat... Casodex Radiation Thera... | 18 Years - | M.D. Anderson Cancer Center | |
| Study of the Effect of Intravenous AVE0005 (VEGF Trap) in Advanced Ovarian Cancer Patients With Recurrent Symptomatic Malignant Ascites | NCT00327444 | Ovarian Neoplas... Ascites | aflibercept (zi... Placebo aflibercept (zi... | 18 Years - | Sanofi | |
| Aflibercept Compared to Placebo in Term of Efficacy in Patients Treated With Gemcitabine for Metastatic Pancreatic Cancer | NCT00574275 | Pancreatic Neop... | Aflibercept (zi... Placebo Gemcitabine | 18 Years - | Sanofi | |
| A Phase 1/2, Open-Label, Dose-Escalation Study of JI-101, in Patients With Advanced Solid Tumors | NCT00842335 | Advanced Solid ... | JI-101 | 18 Years - | Jubilant Innovation Ltd. | |
| Sorafenib to Treat Children and Young Adults With Neurofibromatosis Type 1 and Inoperable Plexiform Neurofibromas | NCT00727233 | Neurofibromatos... Plexiform Neuro... | Nexavar (BAY 43... Toxicity, Pharm... Pharmacodynamic... Radiographic Ev... QOL assessment,... Bony Toxicity | 3 Years - 18 Years | National Institutes of Health Clinical Center (CC) | |
| Trial of TRC105 and Sorafenib in Patients With HCC | NCT02560779 | Hepatocellular ... | Carotuximab (TR... Sorafenib | 18 Years - | Tracon Pharmaceuticals Inc. | |
| A Phase I Study of TAS-102 in Patients With Advanced Gastrointestinal Tumors. | NCT01916447 | Advanced Gastro... | TAS-102 CPT-11 Bevacizumab | 18 Years - | Taiho Oncology, Inc. | |
| Study of the Effect of Intravenous AVE0005 (VEGF Trap) in Advanced Ovarian Cancer Patients With Recurrent Symptomatic Malignant Ascites | NCT00327444 | Ovarian Neoplas... Ascites | aflibercept (zi... Placebo aflibercept (zi... | 18 Years - | Sanofi | |
| Sorafenib to Treat Children and Young Adults With Neurofibromatosis Type 1 and Inoperable Plexiform Neurofibromas | NCT00727233 | Neurofibromatos... Plexiform Neuro... | Nexavar (BAY 43... Toxicity, Pharm... Pharmacodynamic... Radiographic Ev... QOL assessment,... Bony Toxicity | 3 Years - 18 Years | National Institutes of Health Clinical Center (CC) |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
